Effectiveness of Tanacetum parthenium on inflammatory and coagulating indexes

Phase 3

• Conditions: Healthy individuals.

• Registration Number: IRCT20140715018490N5
• Lead Sponsor: Vice chancellor for research, Fasa University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 11 September 2018

Recruitment & Eligibility

• Status: Complete
• Sex: Male
• Target Recruitment: 60

Inclusion Criteria

age between20 and 60
negative hx of D.M
negative hx of major surgery(Under 6 months)
negative hx of HTN
negative hx of coagulopathy like hemophilia
negative hx of liver diseases
Satisfaction to participate in the scheme.
not use anticoaglant drugs and anti inflamatory drugs such as NSAIDs
Not to have bleeding disorders in GI system

Exclusion Criteria

positive hx of coagulopathy like hemophilia
positive hx of HTN
positive hx of major surgery(Under 6 months)
positive hx of D.M
liver disease such as cirihosis or hepatitis
Age over 60 or under the age of 20
use anticoaglant drugs and anti inflamatory drugs such as NSAIDs
Dissatisfaction to participate in the scheme
To have bleeding disorders in GI system
possible complications

Study & Design

• Study Type: interventional
• Study Design: Not specified